CA2873896A1 - Methodes de traitement ou de prediction de risque d'un evenement de tachyarythmie ventriculaire - Google Patents

Methodes de traitement ou de prediction de risque d'un evenement de tachyarythmie ventriculaire Download PDF

Info

Publication number
CA2873896A1
CA2873896A1 CA2873896A CA2873896A CA2873896A1 CA 2873896 A1 CA2873896 A1 CA 2873896A1 CA 2873896 A CA2873896 A CA 2873896A CA 2873896 A CA2873896 A CA 2873896A CA 2873896 A1 CA2873896 A1 CA 2873896A1
Authority
CA
Canada
Prior art keywords
level
subject
soluble
biological sample
additional biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873896A
Other languages
English (en)
Inventor
James V. Snider
Timothy Edward MEYER
Craig Michael STOLEN
Robert W. Gerwien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiac Pacemakers Inc
Critical Care Diagnostics Inc
Original Assignee
Cardiac Pacemakers Inc
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers Inc, Critical Care Diagnostics Inc filed Critical Cardiac Pacemakers Inc
Publication of CA2873896A1 publication Critical patent/CA2873896A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39—Heart defibrillators
    • A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
CA2873896A 2012-05-18 2013-05-17 Methodes de traitement ou de prediction de risque d'un evenement de tachyarythmie ventriculaire Abandoned CA2873896A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649202P 2012-05-18 2012-05-18
US61/649,202 2012-05-18
PCT/US2013/041686 WO2013173778A1 (fr) 2012-05-18 2013-05-17 Méthodes de traitement ou de prédiction de risque d'un événement de tachyarythmie ventriculaire

Publications (1)

Publication Number Publication Date
CA2873896A1 true CA2873896A1 (fr) 2013-11-21

Family

ID=49584355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873896A Abandoned CA2873896A1 (fr) 2012-05-18 2013-05-17 Methodes de traitement ou de prediction de risque d'un evenement de tachyarythmie ventriculaire

Country Status (11)

Country Link
US (3) US20130345805A1 (fr)
EP (2) EP3434260A1 (fr)
JP (2) JP6302896B2 (fr)
CN (2) CN109212223B (fr)
AU (2) AU2013262515B2 (fr)
CA (1) CA2873896A1 (fr)
ES (1) ES2709697T3 (fr)
HK (1) HK1208624A1 (fr)
IN (1) IN2014DN09776A (fr)
MX (1) MX357740B (fr)
WO (1) WO2013173778A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
AU2003234407B2 (en) 2002-05-09 2008-12-18 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
EP2386860B1 (fr) 2006-04-24 2014-11-05 Critical Care Diagnostics, Inc. Prédiction de la mortalité et détection de maladies graves
WO2007143295A2 (fr) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukine-33 (il-33) utilisée pour le diagnostic et le pronostic des maladies cardiovasculaires
EP2021796B1 (fr) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Procédé de diagnostic d'une maladie cardiovasculaire
SI2269063T1 (sl) 2008-04-18 2014-01-31 Critical Care Diagnostics, Inc. Napoved tveganja večjih neugodnih pojavov na srcu
CN103154027B (zh) * 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
WO2012141844A2 (fr) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Procédés de prédiction de risque d'un résultat clinique indésirable
CN106908604B (zh) 2011-07-18 2019-01-29 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
EP2809393B1 (fr) 2012-01-31 2016-11-30 Cardiac Pacemakers, Inc. Systèmes et procédés de resynchronisation cardiaque avec controle de données de groupe de biomarqueurs
WO2013116547A1 (fr) * 2012-01-31 2013-08-08 Cardiac Pacemakers, Inc. Dispositif implantable et procédés de diagnostic d'une insuffisance cardiaque sur la base des données issues d'un panel de biomarqueurs
WO2013173778A1 (fr) * 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Méthodes de traitement ou de prédiction de risque d'un événement de tachyarythmie ventriculaire
ES2656897T3 (es) 2012-08-16 2018-02-28 Critical Care Diagnostics, Inc. Procedimientos de predicción del riesgo de desarrollar hipertensión
IN2015DN01767A (fr) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10188863B2 (en) 2015-02-26 2019-01-29 Medtronic, Inc. Therapy program selection for electrical stimulation therapy based on a volume of tissue activation
JP7009977B2 (ja) * 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
WO2020097190A1 (fr) * 2018-11-06 2020-05-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Procédé de traitement personnalisé de la cardiomyopathie et de l'insuffisance cardiaque et de maladies associées par mesure d'un œdème et de la cachexie/ sarcopénie
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
AU2003234407B2 (en) 2002-05-09 2008-12-18 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
WO2005041893A2 (fr) 2003-10-31 2005-05-12 Queststar Medical, Inc. Detection des biomarqueurs de l'infarctus aigu du myocarde
EP1723432A1 (fr) * 2004-02-05 2006-11-22 Medtronic, Inc. Methodes et appareil permettant d'identifier des patients presentant un risque de developper des arythmies mettant leur vie en danger
EP2386860B1 (fr) 2006-04-24 2014-11-05 Critical Care Diagnostics, Inc. Prédiction de la mortalité et détection de maladies graves
WO2007143295A2 (fr) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukine-33 (il-33) utilisée pour le diagnostic et le pronostic des maladies cardiovasculaires
EP2021796B1 (fr) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Procédé de diagnostic d'une maladie cardiovasculaire
PL2019965T3 (pl) 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
CA2660691C (fr) 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Moyens et procedes d'evaluation du risque d'interventions cardiaques a partir du gene gdf-15
EP1884777A1 (fr) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Moyens et procédés d'évaluation du risque d'interventions cardiaques basées sur GDF-15
CN110346577A (zh) * 2007-08-03 2019-10-18 B.R.A.H.M.S 有限公司 降钙素原（pct）在患原发性非传染疾病的患者的风险分级和预后中的应用
US20090092998A1 (en) * 2007-09-11 2009-04-09 The United States Of America Department Of Veterans Affairs Marker for arrhythmia risk
EP2107377A1 (fr) * 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Niveaux pro-endothéline 1 pour la prédiction d'un risque d'événements tachyarrhytmiques
SI2269063T1 (sl) 2008-04-18 2014-01-31 Critical Care Diagnostics, Inc. Napoved tveganja večjih neugodnih pojavov na srcu
GB0818650D0 (en) * 2008-10-10 2008-11-19 Uni I Oslo Methods
WO2011103330A2 (fr) * 2010-02-17 2011-08-25 The Johns Hopkins University Nouvelle phosphorylation de la troponine cardiaque i utilisée comme un moniteur de lésion cardiaque
CN103154027B (zh) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
WO2012141844A2 (fr) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Procédés de prédiction de risque d'un résultat clinique indésirable
CN106908604B (zh) 2011-07-18 2019-01-29 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
WO2013173778A1 (fr) * 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Méthodes de traitement ou de prédiction de risque d'un événement de tachyarythmie ventriculaire
ES2656897T3 (es) 2012-08-16 2018-02-28 Critical Care Diagnostics, Inc. Procedimientos de predicción del riesgo de desarrollar hipertensión
IN2015DN01767A (fr) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc

Also Published As

Publication number Publication date
US20130345805A1 (en) 2013-12-26
JP6600709B2 (ja) 2019-10-30
US11340236B2 (en) 2022-05-24
ES2709697T3 (es) 2019-04-17
AU2013262515A1 (en) 2014-12-04
EP2849729B1 (fr) 2018-11-14
US20190391162A1 (en) 2019-12-26
EP2849729A1 (fr) 2015-03-25
WO2013173778A1 (fr) 2013-11-21
MX2014013995A (es) 2015-09-04
MX357740B (es) 2018-07-23
CN104507383B (zh) 2018-08-28
EP3434260A1 (fr) 2019-01-30
CN109212223A (zh) 2019-01-15
AU2018204145A1 (en) 2018-06-28
US10408845B2 (en) 2019-09-10
JP2015520371A (ja) 2015-07-16
US20170146552A1 (en) 2017-05-25
JP6302896B2 (ja) 2018-03-28
IN2014DN09776A (fr) 2015-07-31
CN109212223B (zh) 2021-11-12
EP2849729A4 (fr) 2016-01-20
HK1208624A1 (en) 2016-03-11
CN104507383A (zh) 2015-04-08
JP2018119976A (ja) 2018-08-02
AU2013262515B2 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
US11340236B2 (en) Methods for treating or predicting risk of a ventricular tachyarrhythmia event
JP6757757B2 (ja) 高血圧症を発症するリスクを予測するための方法
ES2750126T3 (es) Procedimientos de predicción del riesgo de un resultado clínico adverso
van den Berg et al. Extracellular matrix remodeling precedes atrial fibrillation: results of the PREDICT-AF trial
Semler et al. A Novel Method Using the Valsalvagram in the Diagnosis of Heart Failure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180516

FZDE Discontinued

Effective date: 20200831